Cerdulatinib yields 'encouraging' results in CTCL, PTCL

3 Views
administrator
administrator
08/09/23

The spleen tyrosine kinase/Janus kinase inhibitor cerdulatinib has demonstrated activity against relapsed and refractory T-cell lymphomas. In a phase 2 trial, cerdulatinib produced responses in 34% of patients with peripheral T-cell lymphoma (PTCL) and 26% of those with cutaneous T-cell lymphoma (CTCL). Learn more at www.mdedge.com/hematology-oncology.

Show more
0 Comments Sort By

    No comments found

    Facebook Comments

    Up next

    Screening for Anal Cancer: When to Screen and What to Do With the Results
    00:36:55
    Screening for Anal Cancer: When to Screen and What to Do With the Results
    administrator
    1 Views
    DART desmoid tumor results: anti-CTLA-4 and anti-PD-1 blockade in rare tumors
    00:02:00
    DART desmoid tumor results: anti-CTLA-4 and anti-PD-1 blockade in rare tumors
    administrator
    1 Views
    Episode 14 - Ewing Sarcoma Phase 3 Clinical Trial - Discussing The Results
    00:46:23
    Episode 14 - Ewing Sarcoma Phase 3 Clinical Trial - Discussing The Results
    administrator
    3 Views
    Why Do Biopsy Results Take So Long? (How Long? Up to 7 Days)
    00:06:12
    Why Do Biopsy Results Take So Long? (How Long? Up to 7 Days)
    administrator
    0 Views
    What are “false-positive” results in cervical cancer screening?
    00:09:03
    What are “false-positive” results in cervical cancer screening?
    administrator
    1 Views
    Cone Biopsy Experience & Results | Cervical Cancer Screening
    00:06:14
    Cone Biopsy Experience & Results | Cervical Cancer Screening
    administrator
    3 Views
    Do People of Color Have an Earlier Onset of CTCL? (Chapter 8)
    00:03:06
    Do People of Color Have an Earlier Onset of CTCL? (Chapter 8)
    administrator
    3 Views
    CTCL Presentation Varies Widely Among Patients, Even Within Subtypes
    00:02:51
    CTCL Presentation Varies Widely Among Patients, Even Within Subtypes
    administrator
    2 Views
    The Importance of Collaboration in Treating CTCL (Chapter 7)
    00:02:30
    The Importance of Collaboration in Treating CTCL (Chapter 7)
    administrator
    3 Views
    The CTCL diagnosis journey
    00:00:20
    The CTCL diagnosis journey
    administrator
    6 Views
    Unmet needs for late-stage CTCL
    00:01:10
    Unmet needs for late-stage CTCL
    administrator
    3 Views
    Miles Prince, MD, explains the outcomes of the ALCANZA study in CD30-expressing CTCL
    00:01:16
    Miles Prince, MD, explains the outcomes of the ALCANZA study in CD30-expressing CTCL
    administrator
    2 Views
    Swaminathan P. Iyer, MD, regarding improvements in the treatment of CTCL
    00:01:35
    Swaminathan P. Iyer, MD, regarding improvements in the treatment of CTCL
    administrator
    4 Views
    FDA Approvals in CML, CTCL, CMV Infection, and Tumor Assay, and Clinical Holds Lifted
    00:08:49
    FDA Approvals in CML, CTCL, CMV Infection, and Tumor Assay, and Clinical Holds Lifted
    administrator
    10 Views
    Pre-clinical activity of tipifarnib in CTCL
    00:02:12
    Pre-clinical activity of tipifarnib in CTCL
    administrator
    5 Views
    CTCL 06 2017
    02:28:08
    CTCL 06 2017
    administrator
    1 Views
    Brentuximab vedotin for CTCL
    00:02:30
    Brentuximab vedotin for CTCL
    administrator
    2 Views
    Clonal evolution in patients with CTCL
    00:02:24
    Clonal evolution in patients with CTCL
    administrator
    3 Views
    RESMAIN: HDAC inhibitor resminostat for CTCL
    00:01:23
    RESMAIN: HDAC inhibitor resminostat for CTCL
    administrator
    1 Views